{"id":8012,"date":"2023-12-05T12:44:15","date_gmt":"2023-12-05T12:44:15","guid":{"rendered":"https:\/\/dailyai.com\/?p=8012"},"modified":"2023-12-05T12:48:06","modified_gmt":"2023-12-05T12:48:06","slug":"astrazeneca-bets-247m-on-ai-company-developing-cancer-drug","status":"publish","type":"post","link":"https:\/\/dailyai.com\/es\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","title":{"rendered":"AstraZeneca apuesta $247m en una empresa de IA que desarrolla un f\u00e1rmaco contra el c\u00e1ncer"},"content":{"rendered":"<p><strong>AstraZeneca ha comprometido $247 millones para financiar los esfuerzos de la empresa de descubrimiento de f\u00e1rmacos de IA Absci para desarrollar un anticuerpo contra el c\u00e1ncer.<\/strong><\/p>\n<p>Absci utiliza su <a href=\"https:\/\/dailyai.com\/es\/2023\/07\/ai-accelerates-discovery-of-anti-aging-drugs-in-new-study\/\">Descubrimiento de f\u00e1rmacos con IA<\/a> para descubrir posibles nuevos f\u00e1rmacos y validarlos en sus laboratorios h\u00famedos.<\/p>\n<p>Con el proyecto respaldado por AstraZeneca, Absci intentar\u00e1 crear un anticuerpo que se una a una diana oncol\u00f3gica espec\u00edfica. La empresa a\u00fan no ha revelado a qu\u00e9 tipo de c\u00e1ncer se dirige este proyecto.<\/p>\n<p>Los anticuerpos son una perspectiva atractiva para <a href=\"https:\/\/dailyai.com\/es\/2023\/06\/researchers-build-breakthrough-ai-model-for-drug-discovery\/\">nuevos medicamentos<\/a> porque son muy selectivos en las dianas a las que se unen y producen efectos inmunog\u00e9nicos m\u00ednimos. Sin embargo, encontrar un nuevo anticuerpo f\u00e1cilmente fabricable con propiedades espec\u00edficas es dif\u00edcil.<\/p>\n<p>El n\u00famero de combinaciones posibles de prote\u00ednas para fabricar anticuerpos es pr\u00e1cticamente ilimitado. As\u00ed que encontrar uno que haga lo que usted quiere que haga implica algunas conjeturas educadas y ensayo y error.<\/p>\n<p>Esto hace que el descubrimiento tradicional de anticuerpos requiera mucho tiempo y recursos. Consiste en cribar grandes bibliotecas inmunol\u00f3gicas o sint\u00e9ticas para encontrar posibles anticuerpos candidatos. Estos candidatos deben sintetizarse antes de confirmar si se unir\u00e1n de forma \u00f3ptima a la diana.<\/p>\n<p>La plataforma de Creaci\u00f3n Integrada de F\u00e1rmacos de Absci utiliza modelos de aprendizaje autom\u00e1tico entrenados en ensayos de laboratorio h\u00famedo, o procedimientos experimentales, que generan miles de millones de datos de interacci\u00f3n prote\u00edna-prote\u00edna.<\/p>\n<p>El modelo de IA aprende los principios de ingenier\u00eda subyacentes que hacen que las distintas prote\u00ednas se comporten como lo hacen. La plataforma utiliza su motor de IA generativa para crear anticuerpos sint\u00e9ticos de novo, o partiendo de cero, en un enfoque de disparo cero.<\/p>\n<p>En el caso de los anticuerpos, un enfoque de \"disparo cero\" significa que las prote\u00ednas candidatas que genera la IA se basan en los primeros principios, en lugar de basarse en datos hist\u00f3ricos de otras prote\u00ednas que se sabe que se unen a un pat\u00f3geno espec\u00edfico.<\/p>\n<p>El uso de la IA permite \"adivinar\" de forma mucho m\u00e1s r\u00e1pida y precisa qu\u00e9 prote\u00ednas podr\u00eda merecer la pena investigar, en comparaci\u00f3n con el m\u00e9todo humano de acertar y fallar.<\/p>\n<p>A continuaci\u00f3n, las prote\u00ednas candidatas se validan experimentalmente en los laboratorios h\u00famedos de Absci. La plataforma de dise\u00f1o de prote\u00ednas con IA acelera el descubrimiento de f\u00e1rmacos al completar el ciclo de recopilaci\u00f3n de datos, dise\u00f1o basado en IA y validaci\u00f3n en laboratorio h\u00famedo en unas seis semanas.<\/p>\n<p>En relaci\u00f3n con su asociaci\u00f3n con AstraZeneca, Sean McClain, director general de Absci, declar\u00f3: \"AstraZeneca es l\u00edder en el desarrollo de tratamientos novedosos en oncolog\u00eda, y nos entusiasma colaborar con ellos en el dise\u00f1o de un anticuerpo candidato terap\u00e9utico con potencial para mejorar la vida de los pacientes con c\u00e1ncer\".<\/p>\n<p>El compromiso financiero de AstraZeneca con el proyecto es una se\u00f1al prometedora de que la empresa es optimista sobre las posibilidades de \u00e9xito. Utilizar la IA para acelerar el desarrollo de <a href=\"https:\/\/dailyai.com\/es\/2023\/08\/ai-powered-blood-test-detects-cancers-in-single-dna-molecules\/\">c\u00e1ncer<\/a> tendr\u00e1 un gran impacto en la vida de los pacientes, as\u00ed como en las finanzas de las grandes farmac\u00e9uticas.<\/p>","protected":false},"excerpt":{"rendered":"<p>AstraZeneca ha comprometido $247 millones para financiar los esfuerzos de la empresa de descubrimiento de f\u00e1rmacos mediante IA Absci para desarrollar un anticuerpo contra el c\u00e1ncer. Absci utiliza su plataforma generativa de descubrimiento de f\u00e1rmacos mediante IA para descubrir posibles nuevos medicamentos y validarlos en sus laboratorios. Con el proyecto respaldado por AstraZeneca, Absci intentar\u00e1 crear un anticuerpo que se una a una diana oncol\u00f3gica espec\u00edfica. La empresa a\u00fan no ha revelado a qu\u00e9 tipo de c\u00e1ncer se dirige este proyecto. Los anticuerpos son una perspectiva atractiva para nuevos f\u00e1rmacos porque son muy selectivos en las dianas a las que se unen y producen efectos inmunog\u00e9nicos m\u00ednimos. Sin embargo, encontrar un<\/p>","protected":false},"author":6,"featured_media":8014,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[84],"tags":[150,203,107],"class_list":["post-8012","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-ai-benefits","tag-biotech","tag-generative-ai"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AstraZeneca bets $247m on AI company developing cancer drug | DailyAI<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dailyai.com\/es\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dailyai.com\/es\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"DailyAI\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-05T12:44:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-05T12:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"501\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Eugene van der Watt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:site\" content=\"@DailyAIOfficial\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Eugene van der Watt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"author\":{\"name\":\"Eugene van der Watt\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\"},\"headline\":\"AstraZeneca bets $247m on AI company developing cancer drug\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"},\"wordCount\":434,\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"keywords\":[\"AI benefits\",\"Biotech\",\"Generative AI\"],\"articleSection\":[\"Industry\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\",\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"datePublished\":\"2023-12-05T12:44:15+00:00\",\"dateModified\":\"2023-12-05T12:48:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/antibody-proteins.jpg\",\"width\":1000,\"height\":501},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/2023\\\/12\\\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/dailyai.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca bets $247m on AI company developing cancer drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#website\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"name\":\"DailyAI\",\"description\":\"Your Daily Dose of AI News\",\"publisher\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/dailyai.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#organization\",\"name\":\"DailyAI\",\"url\":\"https:\\\/\\\/dailyai.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/06\\\/Daily-Ai_TL_colour.png\",\"width\":4501,\"height\":934,\"caption\":\"DailyAI\"},\"image\":{\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/DailyAIOfficial\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/dailyaiofficial\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@DailyAIOfficial\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/#\\\/schema\\\/person\\\/7ce525c6d0c79838b7cc7cde96993cfa\",\"name\":\"Eugene van der Watt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"url\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"contentUrl\":\"https:\\\/\\\/dailyai.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/Eugine_Profile_Picture-96x96.png\",\"caption\":\"Eugene van der Watt\"},\"description\":\"Eugene comes from an electronic engineering background and loves all things tech. When he takes a break from consuming AI news you'll find him at the snooker table.\",\"sameAs\":[\"www.linkedin.com\\\/in\\\/eugene-van-der-watt-16828119\"],\"url\":\"https:\\\/\\\/dailyai.com\\\/es\\\/author\\\/eugene\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AstraZeneca apuesta $247m en una empresa de IA que desarrolla un f\u00e1rmaco contra el c\u00e1ncer | DailyAI","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dailyai.com\/es\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_locale":"es_ES","og_type":"article","og_title":"AstraZeneca bets $247m on AI company developing cancer drug | DailyAI","og_description":"AstraZeneca has committed $247 million to fund AI drug discovery company Absci\u2019s efforts to develop an antibody for cancer. Absci uses its generative AI drug discovery platform to discover potential new drugs and then validates these in its wet-labs. With the AstraZeneca-backed project, Absci will try to create an antibody that binds to a specific oncology target. The company hasn\u2019t yet revealed which type of cancer it is targeting with this project. Antibodies are an attractive prospect for new drugs because they are highly selective in the targets they bind to and result in minimal immunogenic effects. However, finding an","og_url":"https:\/\/dailyai.com\/es\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","og_site_name":"DailyAI","article_published_time":"2023-12-05T12:44:15+00:00","article_modified_time":"2023-12-05T12:48:06+00:00","og_image":[{"width":1000,"height":501,"url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","type":"image\/jpeg"}],"author":"Eugene van der Watt","twitter_card":"summary_large_image","twitter_creator":"@DailyAIOfficial","twitter_site":"@DailyAIOfficial","twitter_misc":{"Escrito por":"Eugene van der Watt","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#article","isPartOf":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"author":{"name":"Eugene van der Watt","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa"},"headline":"AstraZeneca bets $247m on AI company developing cancer drug","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"},"wordCount":434,"publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","keywords":["AI benefits","Biotech","Generative AI"],"articleSection":["Industry"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","url":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/","name":"AstraZeneca apuesta $247m en una empresa de IA que desarrolla un f\u00e1rmaco contra el c\u00e1ncer | DailyAI","isPartOf":{"@id":"https:\/\/dailyai.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"image":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","datePublished":"2023-12-05T12:44:15+00:00","dateModified":"2023-12-05T12:48:06+00:00","breadcrumb":{"@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#primaryimage","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/12\/antibody-proteins.jpg","width":1000,"height":501},{"@type":"BreadcrumbList","@id":"https:\/\/dailyai.com\/2023\/12\/astrazeneca-bets-247m-on-ai-company-developing-cancer-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dailyai.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca bets $247m on AI company developing cancer drug"}]},{"@type":"WebSite","@id":"https:\/\/dailyai.com\/#website","url":"https:\/\/dailyai.com\/","name":"DailyAI","description":"Su dosis diaria de noticias sobre IA","publisher":{"@id":"https:\/\/dailyai.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dailyai.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/dailyai.com\/#organization","name":"DailyAI","url":"https:\/\/dailyai.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/06\/Daily-Ai_TL_colour.png","width":4501,"height":934,"caption":"DailyAI"},"image":{"@id":"https:\/\/dailyai.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/DailyAIOfficial","https:\/\/www.linkedin.com\/company\/dailyaiofficial\/","https:\/\/www.youtube.com\/@DailyAIOfficial"]},{"@type":"Person","@id":"https:\/\/dailyai.com\/#\/schema\/person\/7ce525c6d0c79838b7cc7cde96993cfa","name":"Eugene van der Watt","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","url":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","contentUrl":"https:\/\/dailyai.com\/wp-content\/uploads\/2023\/07\/Eugine_Profile_Picture-96x96.png","caption":"Eugene van der Watt"},"description":"Eugene es ingeniero electr\u00f3nico y le encanta todo lo relacionado con la tecnolog\u00eda. Cuando descansa de consumir noticias sobre IA, lo encontrar\u00e1 jugando al billar.","sameAs":["www.linkedin.com\/in\/eugene-van-der-watt-16828119"],"url":"https:\/\/dailyai.com\/es\/author\/eugene\/"}]}},"_links":{"self":[{"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/posts\/8012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/comments?post=8012"}],"version-history":[{"count":5,"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/posts\/8012\/revisions"}],"predecessor-version":[{"id":8018,"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/posts\/8012\/revisions\/8018"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/media\/8014"}],"wp:attachment":[{"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/media?parent=8012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/categories?post=8012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailyai.com\/es\/wp-json\/wp\/v2\/tags?post=8012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}